Meeting NewsVideo

VIDEO: Kala readies to launch Inveltys for cataract surgery

CHICAGO — At the Ophthalmology Innovation Summit at AAO, Mark Iwicki, chairman and CEO of Kala Pharmaceuticals, discusses the company’s plans to launch Inveltys (loteprednol etabonate ophthalmic suspension 1%), a twice-daily topical steroid, for the treatment of inflammation and pain following cataract surgery.

CHICAGO — At the Ophthalmology Innovation Summit at AAO, Mark Iwicki, chairman and CEO of Kala Pharmaceuticals, discusses the company’s plans to launch Inveltys (loteprednol etabonate ophthalmic suspension 1%), a twice-daily topical steroid, for the treatment of inflammation and pain following cataract surgery.

    See more from Ophthalmology Innovation Summit